Kenvue (KVUE) Receives “Buy” Rating Despite Recent Stock Dip adn Autism Concerns
Table of Contents
Despite recent challenges, including a lowered 2025 guidance and a importent stock drop following reports linking Tylenol use during pregnancy to autism, Goldman Sachs reiterated a “Buy” rating for Kenvue (KVUE). Analyst Lizzul believes the current stock discount presents an attractive entry point for investors, forecasting a potential valuation increase.
Recent Performance and Challenges
Shares of Kenvue, the consumer health company behind brands like Tylenol, Motrin, Band-Aid, Aveeno, and Neutrogena, have declined by 12.8% year-to-date as of today, September 8, 2024. The stock experienced a more than 10% slide on Friday, September 6, 2024, after The Wall Street Journal reported that Health and human Services (HHS) Secretary Robert F. Kennedy Jr. is highly likely to suggest a link between acetaminophen (Tylenol) use during pregnancy and autism WSJ Report. HHS is expected to release a report this month outlining potential causes and treatments for autism.
Goldman Sachs’ Perspective
Lizzul downplayed the potential impact of the HHS report on Kenvue’s stock, noting that the company previously faced similar litigation in 2023.At that time, the Food and Drug Administration (FDA) reaffirmed its findings, stating there was no conclusive evidence to support a causal relationship between acetaminophen use during pregnancy and an increased risk of Autism Spectrum Disorder (ASD) or Attention-Deficit/Hyperactivity Disorder (ADHD) FDA Statement on Acetaminophen.
According to Lizzul, a third-party litigation expert indicated that establishing causality requires further scientific evidence and the absence of othre contributing factors. Kenvue maintains that Tylenol is safe when used as directed.
Goldman Sachs values KVUE with a 13x CY26e EV/EBITDA multiple, a premium compared to its current valuation of 11x. The firm anticipates improving, though still negative, organic sales through 2025 and views the lowered 2025 guidance as achievable.
Key Takeaways
“Buy” Rating Maintained: Goldman sachs reaffirms its “Buy” rating for Kenvue despite recent challenges.
Stock Dip as Chance: The current stock price is seen as an attractive entry point due to a widening discount.
Autism Link Concerns Downplayed: Analysts believe the HHS report will not materially affect the stock, citing previous FDA findings and the need for further scientific evidence.
Valuation Potential: Goldman Sachs projects a higher valuation for Kenvue based on a 13x CY26e EV/EBITDA multiple.
Looking Ahead
While the concerns surrounding a potential link between Tylenol and autism have understandably impacted investor sentiment,the analysis suggests these concerns are likely overblown. Kenvue’s strong brand portfolio and Goldman Sachs’ positive outlook indicate potential for recovery and growth. Investors will be closely watching the release of the HHS report and Kenvue’s performance in the coming quarters.